statin

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
PCSK9 Inhibitor with Statin Therapy for Asymptomatic Intracranial Atherosclerosis	2025/03/30	NCT06902740	Phase 4	Not yet recruiting	Peking Union Medical College Hospital
Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study	2025/01/21	NCT06785740	N/A	Recruiting	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)	2024/12/18	NCT06738758	N/A	Recruiting	Yun Dai Chen
Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)	2024/12/12	NCT06730802	Not Applicable	Not yet recruiting	Nanjing Medical University
Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke	2024/09/19	NCT06604117	N/A	Recruiting	Xuanwu Hospital, Beijing
Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy	2024/08/14	NCT06553157	Phase 1	Recruiting	Minia University
Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography	2024/07/25	NCT06520904	Phase 4	Recruiting	First Affiliated Hospital of Xinjiang Medical University
An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian Cancer	2024/06/21	NCT06468254	Phase 2	Recruiting	Anhui Provincial Cancer Hospital
Statins and Post-ERCP Acute Pancreatitis (Stark Project)	2024/04/16	NCT06367322	N/A	Completed	Hospital General Universitario de Alicante
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)	2024/02/28	NCT06280976	Phase 4	Withdrawn	University of Louisville

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Merck's Enlicitide Shows Promise as First Oral PCSK9 Inhibitor in Phase 3 Trials

a month ago

Merck's enlicitide decanoate achieved statistically significant and clinically meaningful LDL cholesterol reductions in two Phase 3 CORALreef trials, potentially becoming the first approved oral PCSK9 inhibitor.

Immediate Statin Therapy Reduces Cardiovascular Events by One-Third in Diabetes Patients

2 months ago

Mass General Brigham researchers analyzed over 7,000 diabetes patients and found immediate statin therapy reduced heart attack and stroke risk by one-third compared to delayed treatment.

AstraZeneca Advances AZD0780 Cholesterol-Lowering Drug Through Phase II and III Clinical Trials

2 months ago

AstraZeneca is conducting a Phase II crossover study evaluating AZD0780's effect on blood pressure in approximately 30 US sites, targeting patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol levels.

Lipoprotein(a): The Overlooked Cardiovascular Risk Factor Gaining Clinical Recognition

4 months ago

Elevated lipoprotein(a) affects approximately 20% of adults and is primarily genetically determined, serving as a significant risk marker for atherosclerotic cardiovascular disease, aortic stenosis, heart failure, and atrial fibrillation.

Cardiovascular Polypill Shows Cost-Effectiveness for Low-Income and Black Populations

6 months ago

New research demonstrates a cardiovascular polypill combining statins and antihypertensive medications is highly cost-effective at $8,560 per QALY gained for managing CVD in low-income and Black populations.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access